Study guide

5.1 Pharmacokinetics & Pharmacodynamics

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

5.1 Pharmacokinetics & Pharmacodynamics

Key Takeaways Explain This Topic AI

Bioavailability (F) represents the fraction of an administered dose reaching systemic circulation unchanged; intravenous administration provides 100% bioavailability by definition (F = 1.0).

Apparent volume of distribution (Vd = Dose / C0) dictates the loading dose required to achieve target plasma concentrations (Loading Dose = [Vd x Target C] / F); lipophilic drugs possess massive Vd (> 5 L/kg) exceeding total body water.

Elimination half-life depends on both distribution volume and clearance (t1/2 = [0.693 x Vd] / CL); steady-state concentration (Css) is achieved after 4 to 5 half-lives, independent of dosage size or dosing frequency.

First-order elimination clears a constant fraction of drug per unit time (exponential decline), whereas zero-order kinetics demonstrates capacity-limited, saturable clearance at a constant amount per unit time (phenytoin, ethanol, high-dose salicylates).

Competitive antagonists cause a parallel rightward shift in the log concentration-response curve (increasing EC50 without altering Emax), whereas non-competitive antagonists depress maximal efficacy (reduced Emax) without shifting EC50.

Last updated: September 2026

Note

Curriculum Focus : The MRCP(UK) Part 1 examination consistently tests quantitative clinical pharmacology. Candidates must be proficient in calculating loading and maintenance doses, manipulating clearance and half-life formulas, identifying the physiological implications of volume of distribution and protein binding, recognizing capacity-limited zero-order elimination, and interpreting log concentration-response curves for various receptor ligands.

Pharmacology is traditionally divided into two reciprocal disciplines: pharmacokinetics (what the body does to the drug: absorption, distribution, metabolism, and excretion) and pharmacodynamics (what the drug does to the body: receptor binding, signal transduction, and physiological response).

Bioavailability and Drug Absorption

Bioavailability (F) is defined as the fraction or percentage of an administered drug dose that gains access to the systemic circulation in an unchanged, chemically active form: Bioavailability (F) = (AUC_oral / AUC_IV) x (Dose_IV / Dose_oral) x 100%

Where AUC represents the Area Under the Plasma Concentration-Time Curve. For intravenous administration, bioavailability is 100% (F = 1.0) by definition. For oral administration, F is typically < 1.0 due to two physiological barriers:

Incomplete Transmucosal Absorption : Caused by poor gastrointestinal membrane permeability, physicochemical degradation (e.g., gastric acid degradation of benzylpenicillin), chelation with divalent cations (e.g., ciprofloxacin or doxycycline binding oral calcium or iron), or active mucosal efflux by apical P-glycoprotein (ABCB1) .

First-Pass Hepatic Metabolism (Pre-systemic Extraction) : Venous drainage from the stomach, small intestine, and upper rectum traverses the hepatic portal vein directly through the liver prior to entering the systemic circulation. Drugs with high hepatic extraction ratios (EH > 0.7) undergo extensive phase I/II enzymatic clearance on their first pass, drastically lowering systemic bioavailability:

High First-Pass Clearance Drugs : Propranolol (F ≈ 25%), lidocaine (F < 10%, hence unusable orally), morphine (F ≈ 20–40%), glyceryl trinitrate (F < 1%, mandating sublingual or transdermal delivery), verapamil, and salbutamol.

Clinical Implication : In severe hepatic cirrhosis with portosystemic shunting, the first-pass effect is lost, leading to dramatic elevations in peak plasma concentrations (Cmax) and unexpected toxicity from routine oral doses of high-clearance drugs.

Apparent Volume of Distribution (Vd)

The apparent volume of distribution (Vd) represents the theoretical volume of fluid into which an administered dose would need to be uniformly distributed to produce the observed initial plasma concentration (C0): Vd = Dose_IV / C0 = (F x Dose_oral) / C0

Vd does not correspond to an anatomical fluid compartment; rather, it reflects the degree to which a drug partitions into extravascular tissues versus remaining sequestered within plasma.

Physiological Compartment Fluid Volume (70 kg adult) Example Drugs & Characteristics

Plasma Volume ~3–4 Litres (0.05 L/kg) Heparin, Warfarin, Monoclonal antibodies . Confined to intravascular space due to high molecular weight (> 50,000 Da) or extensive albumin binding (> 98%).

Extracellular Fluid (ECF) ~14 Litres (0.2 L/kg) Aminoglycosides (Gentamicin), Vancomycin . Highly polar, water-soluble (hydrophilic) molecules that cross capillary fenestrations but cannot readily penetrate lipophilic cell membranes.

Total Body Water (TBW) ~42 Litres (0.6 L/kg) Ethanol, Phenytoin, Lithium, Theophylline . Small, uncharged molecules that equilibrate freely across cell membranes throughout all fluid spaces.

Deep Tissue Sequestration > 42 to > 5,000 Litres (> 5–50 L/kg) Digoxin (~5–7 L/kg), Amiodarone (~70 L/kg), Chloroquine (~100–200 L/kg), Tricyclic antidepressants . Highly lipophilic drugs that bind avidly to intracellular tissue proteins, lipids, or skeletal muscle, leaving negligible free drug in plasma.

Plasma Protein Binding and the Free Drug Fraction

Only the unbound ( free ) fraction of a drug can cross vascular membranes to reach therapeutic target receptors, undergo glomerular filtration, or enter hepatocytes for enzymatic biotransformation.

Acidic Drugs : Bind predominantly to albumin (e.g., warfarin, phenytoin, salicylates, ceftriaxone, sulfonylureas).

Basic Drugs : Bind predominantly to α1-acid glycoprotein (e.g., lidocaine, propranolol, verapamil, tricyclic antidepressants).

Important

Hypoalbuminaemia & Critical Care Alterations :

In nephrotic syndrome, cirrhosis, systemic sepsis, or severe malnutrition, albumin concentrations fall. For drugs that are > 90% protein-bound (such as phenytoin), total measured serum levels decrease because unbound drug distributes into tissue or is cleared. However, the biologically active free drug concentration often remains completely therapeutic or even supratherapeutic. Measuring total phenytoin without correcting for albumin (or directly checking free phenytoin) risks erroneous dose escalation and severe toxicity.

Loading Dose Formulation

The loading dose is designed to rapidly achieve the target therapeutic steady-state plasma concentration (C_target), bypassing the delay required by elimination half-life accumulation: Loading Dose = (Vd x C_target) / F

Notice that the loading dose depends only on Vd and target concentration; it is completely independent of systemic drug clearance (CL). Therefore, in acute renal failure, the loading dose of digoxin or vancomycin remains identical to that in healthy individuals, whereas the subsequent maintenance doses must be drastically reduced.

Clearance (CL) and Elimination Kinetics

Clearance (CL) is the volume of plasma completely cleared of drug per unit of time (expressed in mL/min or L/h). Total systemic clearance represents the sum of all individual organ elimination pathways: CL_total = CL_renal + CL_hepatic + CL_biliary + CL_other

Clearance is mathematically defined by the relationship between the rate of drug elimination and plasma drug concentration (C): CL = Rate of Elimination / C = (F x Dose) / AUC

Maintenance Dose Rate

To maintain a constant target steady-state concentration (Css), the rate of drug input must precisely equal the rate of drug loss: Dosing Rate (Maintenance) = (CL x Css) / F

  • Maintenance Dose per Interval (tau) = (CL x Css x tau) / F
  • Elimination Half-Life (t1/2) and Steady-State Dynamics

The elimination half-life (t1/2) is the time required for the plasma drug concentration to decrease by 50% under first-order elimination conditions. It is governed by both clearance and volume of distribution: t1/2 = (0.693 x Vd) / CL

From this relationship, two vital clinical axioms emerge for the MRCP examination:

t1/2 is directly proportional to Vd : A drug with a massive volume of distribution (e.g., amiodarone, Vd ≈ 5000 L) will have a prolonged half-life (several weeks) even if organ clearance mechanisms are functional.

t1/2 is inversely proportional to CL : Severe renal impairment decreases aminoglycoside clearance, directly prolonging t1/2 and necessitating extended dosing intervals. +-----------------------------------------------------------------------------------------+

  • | Accumulation to Steady State (Css) |
  • +-----------------------------------------------------------------------------------------+
  • | Time Elapsed: Fraction of Steady State Attained: |
  • | 1 x t1/2 50.0 % |
  • | 2 x t1/2 75.0 % |
  • | 3 x t1/2 87.5 % |
  • | 4 x t1/2 93.75 % |
  • | 5 x t1/2 96.875 % (Clinically considered steady state: > 95%) |
  • +-----------------------------------------------------------------------------------------+

Note

Rule of 5 Half-Lives :

Steady-state plasma concentration (Css) is reached after 4 to 5 half-lives of continuous regular dosing or constant infusion. Crucially, increasing the dose or increasing the rate of infusion does not allow steady state to be reached any faster; it merely produces a proportionately higher steady-state concentration. The time required to reach steady state is determined solely by the elimination half-life of the drug.

First-Order vs Zero-Order (Saturable) Kinetics

Understanding the mathematical divergence between linear and capacity-limited elimination is essential for diagnosing drug toxicities:

Parameter First-Order Elimination (Linear) Zero-Order Elimination (Capacity-Limited / Non-Linear)

Rate of Elimination Proportional to drug concentration (elimination increases as concentration rises) Constant absolute amount eliminated per unit time, regardless of concentration

Fraction Eliminated Constant fraction eliminated per unit time (e.g., 20% per hour) Variable fraction; decreases as plasma concentration increases

Half-Life (t1/2) Constant ; independent of dose or concentration Not constant ; prolongs as plasma concentration rises

Clearance (CL) Constant across therapeutic range Decreases with increasing dose/concentration

Concentration vs Time Curve Exponential decline (linear when plotted on semi-logarithmic axes) Linear decline on arithmetic axes (downward straight line)

Dose-Concentration Relationship Proportional (doubling the dose doubles Css) Disproportionate / Exponential jump once enzymes saturate

Classic Clinical Examples Vast majority (> 95%) of drugs at therapeutic doses Phenytoin, Ethanol, Salicylates (aspirin in overdose) , high-dose fluoxetine Plasma Concentration (C)

  • ^
  • | Zero-Order Phase
  • | (Rate = Vmax = Constant)
  • | / Saturation point
  • | / |
  • | / v
  • | / --------------------
  • | / / First-Order Phase
  • | / / (Rate = CL x C)
  • | / /
  • +-------------------------------------> Dose / Administration Rate
  • Clinical Disaster with Zero-Order Kinetics: Phenytoin
  • Phenytoin follows Michaelis-Menten elimination kinetics : Rate of Elimination = (Vmax x C) / (Km + C)

Where Vmax is the maximum rate of hepatic enzymatic biotransformation (CYP2C9/2C19) and Km is the plasma concentration at which elimination is half-maximal (~20–30 μmol/L, which sits right inside the therapeutic range of 40–80 μmol/L [10–20 mg/L]).

At low concentrations (C << Km), elimination is first-order.

As concentrations enter the therapeutic window (C ≈ Km), enzyme saturation commences.

At high therapeutic concentrations (C >> Km), enzymes are fully saturated (zero-order). At this point, a minor, seemingly harmless dose increment (e.g., from 300 mg to 350 mg daily) overwhelms hepatic clearance capacity, causing a catastrophic, exponential surge in plasma concentration leading to nystagmus, severe cerebellar ataxia, and coma.

Pharmacodynamics: Receptor Interactions & Concentration-Response Curves

Pharmacodynamics evaluates the relationship between drug concentration and biological effect. When biological effect is plotted against the logarithm of drug concentration (log[D]), a characteristic symmetrical sigmoidal (S-shaped) curve is generated.

Key Quantitative Definitions

Efficacy (Emax) : The maximal biological response produced by an agonist at receptor saturation. Reflects intrinsic biological activity.

Potency (EC50) : The concentration of drug required to produce 50% of its maximal effect. A lower EC50 signifies higher potency (the curve lies further to the left). Potency is governed by receptor affinity and spare receptor capacity.

Classification of Ligands and Functional Shifts

Full Agonist : Binds to receptors, stabilizes the active conformational state, and possesses an intrinsic efficacy of 1.0, achieving maximal tissue response (Emax = 100%).

Partial Agonist : Stabilizes the active conformation with lower intrinsic efficacy (0 < efficacy < 1.0). Even when 100% of receptors are occupied, a partial agonist cannot produce maximal tissue response. Clinical Pitfall : In the presence of a full agonist, a partial agonist competes for binding sites and acts as a competitive antagonist , shifting the full agonist's curve rightward while reducing overall response (e.g., buprenorphine attenuating full mu-opioid agonists, pindolol blunting catecholamines, varenicline competing with nicotine).

Inverse Agonist : Preferentially binds to and stabilizes the inactive conformation of constitutively active receptors (receptors that signal even without ligand binding, such as GABAA, cannabinoid, or histamine H2 receptors), driving basal signaling below baseline.

Competitive (Reversible) Antagonist :

Binds reversibly to the same orthosteric agonist binding pocket.

Dose-Response Effect : Produces a parallel rightward shift in the log concentration-response curve.

Parameters : EC50 is increased (apparent potency reduced); Emax remains unchanged (unaffected).

Mechanism : Can be completely overcome ("surmounted") by adding higher concentrations of agonist (e.g., naloxone competing with morphine; atropine competing with acetylcholine).

Non-Competitive (Allosteric or Irreversible) Antagonist :

Binds either irreversibly (covalently) to the active site (e.g., phenoxybenzamine at alpha-adrenoceptors) or reversibly to a separate allosteric site (e.g., ketamine at NMDA receptors).

Dose-Response Effect : Causes a downward crushing / depression of the curve.

Parameters : Emax is reduced ; EC50 remains unchanged (or minimally altered).

Mechanism : Cannot be surmounted by increasing agonist concentration because available functional receptors are permanently silenced. Biological Effect (% Emax)

  • 100 + /-- Full Agonist Alone
  • | /
  • | / /-- Full Agonist + Competitive Antagonist
  • | / / (Parallel Right-Shift: EC50 increased, Emax intact)
  • 50 | / /
  • | / /
  • | /-- Non-Comp / /
  • | / Antagonist
  • |/ (Emax depressed)
  • 0 +-------------------------------------------> log [Drug Concentration]
  • Therapeutic Index (TI)

The margin of safety of a pharmaceutical compound is quantified by the Therapeutic Index : Therapeutic Index = TD50 / ED50 or LD50 / ED50

Where TD50 is the toxic dose in 50% of subjects, and ED50 is the therapeutically effective dose in 50% of subjects. Drugs with a narrow therapeutic index (e.g., warfarin, digoxin, lithium, theophylline, gentamicin, phenytoin, carbamazepine) require meticulous therapeutic drug monitoring (TDM) and precise dosing adjustment.

Loading diagram... Receptor Ligand Pharmacodynamic Concentration-Response Profiles